Ipsen : FY 2025 – Highlights (340.30 KB)

‌"In 2025, Ipsen delivered strong sales and profit growth and continued to execute across all three TAs with a notable performance from Iqirvo."

David Loew FY 2025 Highlights

Geographic Breakdown

€3,676m

+10.9%1

Total sales by region: 2025

Oncology

Rare Disease

Neuroscience

In this map, Europe is defined as the E.U., the U.K.,

North America 35%

of total sales

Europe 40%

of total sales

RoW 25%

of total sales

2025 Regulatory Highlights

Tovorafenib: EMA regulatory submission

Cabometyx®: EU approval in NETs

IPN10200: Proof-of-concept data readout in aesthetics

Chief Executive Officer

Iceland, Liechtenstein, Norway, and Switzerland.

https://www.ipsen.com/investors

TAs: Therapeutic Areas; EMA: European Medicines Agency; EU: European Union; NETs: Neuroendocrine Tumors

1 At constant exchange rates; 2 Excludes any impact of potential late-stage external-innovation opportunities

Henry Wheeler Vice President Investor Relations

Oncology

+4.1%

+4.3%

+5.1%

+2.7%

+6.2%

Rare Disease

+102.5%

€180m

€184m

Neuroscience

+9.7%

Aesthetics

+13.7%

Therapeutics

+4.2%

2026 Guidance2

Total sales growth: >13.0% at CER1

Core operating margin: >35.0% of total sales

[phone]

[e-mail]

Khalid Deojee Senior Manager Investor Relations

[phone]

[e-mail]